Show simple item record

dc.contributor.authorKudling, T. V.
dc.contributor.authorClubb, J. H. A.
dc.contributor.authorQuixabeira, D. C. A.
dc.contributor.authorSantos, J. M.
dc.contributor.authorHavunen, R.
dc.contributor.authorKononov, Alexander
dc.contributor.authorHeiniö, C.
dc.contributor.authorCervera-Carrascon, V.
dc.contributor.authorPakola, S.
dc.contributor.authorBasnet, S.
dc.contributor.authorGrönberg-Vähä-Koskela, S.
dc.contributor.authorArias, V.
dc.contributor.authorGladwyn-Ng, I.
dc.contributor.authorAro, K.
dc.contributor.authorBäck, L.
dc.contributor.authorRäsänen, J.
dc.contributor.authorIlonen, I.
dc.contributor.authorBorenius, K.
dc.contributor.authorRäsänen, M.
dc.contributor.authorHemminki, O.
dc.contributor.authorRannikko, A.
dc.contributor.authorKanerva, A.
dc.contributor.authorTapper, J.
dc.contributor.authorHemminki, A.
dc.date.accessioned2022-08-17T09:45:39Z
dc.date.available2022-08-17T09:45:39Z
dc.date.issued2022en
dc.identifier.citationKudling TV, Clubb JHA, Quixabeira DCA, Santos JM, Havunen R, Kononov A, et al. Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression. Oncoimmunology. 2022;11(1):2096572. PubMed PMID: 35845722. Pubmed Central PMCID: PMC9278414. Epub 2022/07/19. eng.en
dc.identifier.pmid35845722en
dc.identifier.doi10.1080/2162402x.2022.2096572en
dc.identifier.urihttp://hdl.handle.net/10541/625437
dc.description.abstractCytokines have proven to be effective for cancer therapy, however whilst low-dose monotherapy with cytokines provides limited therapeutic benefit, high-dose treatment can lead to a number of adverse events. Interleukin 7 has shown promising results in clinical trials, but anti-cancer effect was limited, in part due to a low concentration of the cytokine within the tumor. We hypothesized that arming an oncolytic adenovirus with Interleukin 7, enabling high expression localized to the tumor microenvironment, would overcome systemic delivery issues and improve therapeutic efficacy. We evaluated the effects of Ad5/3-E2F-d24-hIL7 (TILT-517) on tumor growth, immune cell activation and cytokine profiles in the tumor microenvironment using three clinically relevant animal models and ex vivo tumor cultures. Our data showed that local treatment of tumor bearing animals with Ad5/3- E2F-d24-hIL7 significantly decreased cancer growth and increased frequency of tumor-infiltrating cells. Ad5/3-E2F-d24-hIL7 promoted notable upregulation of pro-inflammatory cytokines, and concomitant activation and migration of CD4+ and CD8 + T cells. Interleukin 7 expression within the tumor was positively correlated with increased number of cytotoxic CD4+ cells and IFNg-producing CD4+ and CD8+ cells. These findings offer an approach to overcome the current limitations of conventional IL7 therapy and could therefore be translated to the clinic.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1080/2162402x.2022.2096572en
dc.titleLocal delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regressionen
dc.typeArticleen
dc.contributor.departmentCancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finlanden
dc.identifier.journalOncoimmunologyen
dc.description.noteen]
refterms.dateFOA2022-08-22T12:20:21Z


Files in this item

Thumbnail
Name:
35845722.pdf
Size:
3.356Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record